Consolidated Capital Management LLC Acquires 616 Shares of Eli Lilly and Company $LLY

Key Points

• Consolidated Capital Management LLC increased its holdings in Eli Lilly by 8% in Q2, owning a total of 8,290 shares valued at approximately $6.46 million.
• Multiple hedge funds raised their positions in Eli Lilly during the second quarter, with notable increases including a 54.8% boost by KG&L Capital Management LLC.
• Eli Lilly recently reported strong quarterly earnings of $6.31 EPS, exceeding estimates and showcasing a 37.6% year-over-year revenue growth to $15.56 billion.

Consolidated Capital Management LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 8.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,290 shares of the company's stock after buying an additional 616 shares during the period. Eli Lilly and Company comprises 2.3% of Consolidated Capital Management LLC's holdings, making the stock its 18th largest holding. Consolidated Capital Management LLC's holdings in Eli Lilly and Company were worth $6,462,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Chatham Capital Group Inc. lifted its holdings in shares of Eli Lilly and Company by 3.5% in the 2nd quarter. Chatham Capital Group Inc. now owns 9,504 shares of the company's stock valued at $7,408,000 after acquiring an additional 317 shares during the last quarter. KG&L Capital Management LLC raised its position in Eli Lilly and Company by 54.8% during the second quarter. KG&L Capital Management LLC now owns 7,583 shares of the company's stock valued at $5,911,000 after purchasing an additional 2,683 shares during the period. LVW Advisors LLC lifted its stake in shares of Eli Lilly and Company by 7.0% in the 2nd quarter. LVW Advisors LLC now owns 3,104 shares of the company's stock valued at $2,420,000 after purchasing an additional 203 shares during the last quarter. Spirepoint Private Client LLC boosted its holdings in shares of Eli Lilly and Company by 2.4% in the 2nd quarter. Spirepoint Private Client LLC now owns 16,156 shares of the company's stock worth $12,594,000 after purchasing an additional 384 shares during the period. Finally, ORG Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 10.0% during the 2nd quarter. ORG Wealth Partners LLC now owns 1,188 shares of the company's stock valued at $922,000 after purchasing an additional 108 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on LLY. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target for the company. in a research note on Sunday, August 17th. Morgan Stanley reiterated an "overweight" rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. UBS Group decreased their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Cantor Fitzgerald dropped their target price on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $939.61.

Insiders Place Their Bets

In other news, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction dated Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gabrielle Sulzberger bought 117 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company's stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Trading Up 1.4%

Shares of LLY opened at $724.73 on Friday. The firm has a market capitalization of $685.93 billion, a price-to-earnings ratio of 47.37, a PEG ratio of 1.01 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The company has a 50-day moving average of $734.15 and a 200 day moving average of $766.82.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the business posted $3.92 EPS. Eli Lilly and Company's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.